神经病理性疼痛的进展与挑战:叙述性综述与未来方向
该叙述性综述回顾了神经病理性疼痛在定义、分类、评估和管理方面的历史与现状进展,指出管理已从经验医学转向循证医学,但靶向现有药物和成功临床开发新靶点药物仍具挑战,并提出合理联合治疗、药物重定位、非药物方法(如神经调控)和个体化治疗等创新策略。
要点
- 神经病理性疼痛的定义和分类已更新并达成共识。
- 已验证问卷改善了急慢性神经病理性疼痛的检测和评估。
- 管理转向循证医学,但靶向药物和新药开发仍具挑战。
核心结论
- 神经病理性疼痛临床研究取得实质性进展,但适当靶向当前药物和成功临床开发作用于新靶点的药物仍具挑战。
- 需要创新方法改进治疗策略,主要包括合理联合治疗、药物重定位、非药物方法(如神经调控技术)和个体化治疗管理。
研究设计与样本
- 叙述性综述,报告神经病理性疼痛定义、分类、评估和管理的历史与当前视角,并探索未来研究潜在途径。
主要发现
- 神经病理性疼痛的更新定义和分类已达成一致。
- 已验证问卷改善了急性和慢性神经病理性疼痛的检测和评估。
- 已描述与COVID-19相关的较新神经病理性疼痛综合征。
- 神经病理性疼痛的管理已从经验医学转向循证医学。
临床怎么用
- 临床可依据更新定义和分类及验证问卷进行神经病理性疼痛的检测与评估。
- 治疗策略可考虑合理联合治疗、药物重定位、非药物方法(如神经调控技术)和个体化治疗管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past few decades, substantial advances have been made in neuropathic pain clinical research. An updated definition and classification have been agreed. Validated questionnaires have improved the detection and assessment of acute and chronic neuropathic pain; and newer neuropathic pain syndromes associated with COVID-19 have been described. The management of neuropathic pain has moved from empirical to evidence-based medicine. However, appropriately targeting current medications and the successful clinical development of drugs acting on new targets remain challenging. Innovative approaches to improving therapeutic strategies are required. These mainly encompass rational combination therapy, drug repurposing, non-pharmacological approaches (such as neurostimulation techniques), and personalised therapeutic management. This narrative review reports historical and current perspectives regarding the definitions, classification, assessment, and management of neuropathic pain and explores potential avenues for future research.
引用
- Attal N, Bouhassira D, Colvin L, et al. Advances and challenges in neuropathic pain: a narrative review and future directions. Br J Anaesth. 2023. PMID: 37210279. doi:10.1016/j.bja.2023.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。